Učitavanje...
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
Gene fusions occur in up to 17% of solid tumours. Oncogenic kinases are often involved in such fusions. In lung cancer, almost 30% of patients carrying an activated oncogene show the fusion of a tyrosine kinase to an heterologous gene. Several genes are partner in the fusion with the three kinases A...
Spremljeno u:
| Izdano u: | Mol Cancer |
|---|---|
| Glavni autori: | , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5817729/ https://ncbi.nlm.nih.gov/pubmed/29455670 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12943-018-0799-8 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|